Clinical trials: Follicular Lymphomas
Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma.
- Trial name
- NCT00430352
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 178 sites in Albania, Argentina and 22 more
- Volunteers
- 545 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma…
- Trial name
- NCT01724021
- Testing
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP), Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP), Bendamustine
- Where
- 246 sites in Argentina, Australia and 30 more
- Volunteers
- 743 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with…
- Trial name
- NCT02187861
- Testing
- Venetoclax, Bendamustine, Rituximab
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Degenerative Disc Disease, Spondylolisthesis, Grade 1
Safety and Efficacy of the CarboClear Pedicle Screw System
The purpose of this trial is to demonstrate the safety and effectiveness of the CarboClear Pedicle Screw System, for skeletally mature DDD patients undergoing one level spinal fusion in combination with interbody fusion device…
- Trial name
- NCT02626624
- Testing
- Implantation of the CarboClear Pedicle Screw System
- Where
- 8 sites in United States, Israel
- Volunteers
- 57 people
- Sponsor
- CarboFix Orthopedics Ltd.
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
- Trial name
- NCT03401853
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Rituximab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Lymphoma, Non-Hodgkin
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
This is a Phase III, multicenter, randomized, double-blind, parallel-arm, active comparator trial to evaluate BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with LTBFL.
- Trial name
- NCT02417129
- Testing
- Rituximab, BI 695500
- Where
- 21 sites in United States, Austria and 4 more
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Leukemia, Lymphoma
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarabine, and a monoclonal antibody, such as alemtuzumab, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00027560
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
- Trial name
- NCT01133158
- Testing
- Rituximab, Bendamustine, Mitoxantrone, Dexamethasone
- Where
- 41 sites in Spain
- Volunteers
- 61 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Follicular Lymphoma, B-cell Lymphoma
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).
- Conditions
- Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT01980654
- Testing
- Ibrutinib, rituximab
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- Pharmacyclics LLC.
Lymphoma, Non-Hodgkins
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma (LG-NHL) that relapse beyond 6 months of a…
- Trial name
- NCT01119794
- Testing
- Ofatumumab and Bortezomib
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Brown University
Follicular Lymphoma, Endometrial Cancer
Study of Copanlisib and Ketogenic Diet
This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R)…
- Trial name
- NCT04750941
- Testing
- Copanlisib, Ketogenic Diet
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
RATIONALE: Biological therapies, such as agatolimod sodium, may stimulate the immune system in different ways and stop cancer cells from growing.
- Conditions
- Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00438880
- Testing
- Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01474681
- Testing
- HSC835
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Large-Cell, Diffuse
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the safety and efficacy of ofatumumab used in combination with ifosfamide, carboplatin, etoposide (ICE) or dexamethasone, cytarabine, cisplatin (DHAP) salvage chemotherapy regimens in…
- Trial name
- NCT00823719
- Testing
- ofatumumab + ICE, ofatumumab + DHAP
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects…
- Trial name
- NCT02780167
- Testing
- PF-04965842
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 269 people
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
This study will determine the overall response rate and toxicity of rituximab and Velcade in combination in patients with relapsed or refractory mantle cell non-Hodgkin's lymphoma.
- Trial name
- NCT00201877
- Testing
- Velcade, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-Hodgkin Lymphoma
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24…
- Trial name
- NCT02406092
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 13 sites in Algeria, Morocco and 1 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.